Heart failure & cardiomyopathiesSecondary analysis
Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
- Secondary analysis of the DAPA-HF randomised trial
Authors' conclusion
Dapagliflozin reduced the total days of potential full health lost due to death, hospitalizations, and impaired well-being, and this benefit increased over time during the first year.
Study context
- Population
- Patients with NYHA class II–IV HF and LVEF ≤40%
- Participants
- 2,127 vs 2,108
- Comparison
- Dapagliflozin vs placebo
- Dapagliflozinn = 2,127
- Placebon = 2,108reference
- Primary endpoint
- Days of full health lost: days lost from death and hospitalization plus days lost through diminished well-being (KCCQ-adjusted)
- Follow-up
- 360 days
Primary result
As reported in the abstract
Days lost through CV death and HF hospitalization
Difference
−3.8 days
95% CI −6.6 to −1.0
By group
Dapagliflozin vs Placebo
difference −3.8 days (95% CI −6.6 to −1.0)
Further findings
Days lost to all-cause death and hospitalization
% Dapagliflozin 4.3% · Placebo 5.6%
Total days of full health lost (KCCQ-overall summary score adjusted)
% Dapagliflozin 30.7% · Placebo 32.5%
Difference in days lost by death and hospitalization over time
- Difference at 120 days
- −0.9 days [−0.7%]
- Difference at 240 days
- −2.3 days [−1.0%]
- Difference at 360 days
- −4.8 days [−1.3%]
Original publication
Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial. J Am Coll Cardiol. Published 25 March 2024. doi:10.1016/j.jacc.2024.03.385
Summarised from the published abstract; every number is checked against it